GADD45alpha mediates arsenite-induced cell apoptotic effect in human hepatoma cells via JNKs/AP-1-dependent pathway
1Department of Cellular Immunology, Beijing Institute of Basic Medical Sciences, 27 Taiping Road, Beijing 100850, PR China.
Abstract:
Arsenite (As(III)), an effective chemotherapeutic agent for the acute promyelocytic leukemia (APL) and multiple myeloma (MM), might be also a promise for the therapy of other cancers, including the solid tumors. However, the molecular bases of arsenite-induced cytotoxicity in the tumor cells have not been fully defined. In this study, we have disclosed that arsenite effectively induces the apoptotic response in the HepG2 human hepatoma cells by triggering GADD45alpha induction and the subsequent activation of JNKs/AP-1 cell death pathway. However, signaling events relating to GADD45alpha/JNKs/AP-1 pathway activation have not been observed in HL7702 human diploid hepatic cells under the same arsenite exposure condition. Our results thus have illustrated the selective pro-apoptotic role of arsenite in the hepatoma cells by activating GADD45alpha-dependent cell death pathway whereas with little effect on the normal hepatic cells. The approaches to up-regulate GADD45alpha levels might be helpful in improving the chemotherapeutic action of arsenite on certain solid tumors including hepatoma.
Insights
Arsenite (As(III)) selectively induces apoptosis in hepatoma cells by activating the GADD45alpha/JNKs/AP-1 pathway. This mechanism offers a promising therapeutic strategy for hepatoma and other solid tumors, sparing normal liver cells.
Area of Science:
- Oncology
- Molecular Biology
- Hepatocellular Carcinoma Research
Background:
- Arsenite (As(III)) is an established chemotherapeutic agent for hematological malignancies like acute promyelocytic leukemia (APL) and multiple myeloma (MM).
- The precise molecular mechanisms underlying arsenite's cytotoxicity in solid tumors, including hepatoma, remain incompletely understood.
- Investigating arsenite's effects on normal versus cancerous liver cells is crucial for understanding its therapeutic potential and limitations.
Purpose of the Study:
- To elucidate the molecular basis of arsenite-induced cytotoxicity in HepG2 human hepatoma cells.
- To investigate the role of the GADD45alpha/JNKs/AP-1 pathway in arsenite's apoptotic effects.
- To determine if arsenite exhibits selective toxicity towards hepatoma cells compared to normal hepatic cells.
Main Methods:
- Exposure of HepG2 human hepatoma cells and HL7702 human diploid hepatic cells to arsenite (As(III)).
- Analysis of GADD45alpha induction and subsequent activation of the JNKs/AP-1 signaling pathway.
- Comparative assessment of arsenite-induced apoptosis in cancer versus normal cells.
Main Results:
- Arsenite effectively induced apoptosis in HepG2 hepatoma cells.
- This apoptotic response was mediated by GADD45alpha induction and activation of the JNKs/AP-1 cell death pathway.
- Similar GADD45alpha/JNKs/AP-1 pathway activation and significant apoptosis were not observed in normal HL7702 hepatic cells.
- Demonstrated selective pro-apoptotic activity of arsenite in hepatoma cells.
Conclusions:
- Arsenite selectively triggers apoptosis in hepatoma cells via the GADD45alpha-dependent cell death pathway.
- The GADD45alpha/JNKs/AP-1 pathway is a key mediator of arsenite's anti-cancer effects in hepatoma.
- Targeting strategies to up-regulate GADD45alpha may enhance arsenite's efficacy in treating hepatoma and other solid tumors.
Related Concept Videos
The Extrinsic Apoptotic Pathway
The Intrinsic Apoptotic Pathway
Apoptosis
MAPK Signaling Cascades
NF-κB-dependent Signaling Pathway
NF-κB-dependent Signaling Mechanism
The heterodimer of NF-κB...
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...

